Iapocec Mavacamten News Today : Breaking News, Live Updates & Top Stories | Vimarsana

From a novel topical gene therapy to a multi-pathway targeting HF drug, the second quarter of 2023 is laden with interesting regulatory decisions.

United statesIapocec mavacamtenPaul feuerstadtKunzmannk sotagliflozinTheodore lengDeepak bhattProfessor of ophthalmology at stanford universityAlexion pharmaceuticalsAmerican academy of dermatologySotagliflozin lexicon pharmaceuticals for heart failureAmerican college of cardiologyDrug administrationYale school of medicineBristol myers squibbSeres therapeuticsRecurrent clostridioides